


PRONOMOS

#ACC20/#WCCardio



AMERICAN
COLLEGE of
CARDIOLOGY

Trial Description: Patients immobilized after nonmajor orthopedic surgery were randomized to rivaroxaban 10 mg daily/enoxaparin placebo vs. enoxaparin 4000 IU subcutaneous daily/rivaroxaban placebo.



RESULTS

- Primary efficacy outcome, major venous thromboembolism (VTE): 0.2% of the rivaroxaban group vs. 1.1% of the enoxaparin group (p = 0.01)
- Primary safety outcome, major or clinically relevant nonmajor bleeding: 1.1% of the rivaroxaban group vs. 1.0% of the enoxaparin group (p = 0.62)

CONCLUSIONS

- Among patients immobilized after nonmajor orthopedic surgery, rivaroxaban compared with enoxaparin was associated with a reduction in major VTE
- Major bleeding was similar between treatment groups

Samama CM, et al. N Engl J Med 2020;Mar 29:[Epub]